YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ernexa Therapeutics Inc. Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further str…
DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics(NASDAQ: ERNA), and VivoSim Labs(NASDAQ: VIVS) highlight three distinct pathways to potential…
Investing.com -- U.S. stock index futures edged higher on Wednesday after softer inflation data and a strong start to the corporate earnings season boosted investor sentiment, with markets weighing whether resilient corporate profits can c…
(RTTNews) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised its clinical data readout timeline, amon…
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progre…
Ernexa Therapeutics’ ERNA shares rallied 140.2% in a month, primarily driven by encouraging preclinical results for its lead cell therapy candidate, ERNA-101, in ovarian cancer. The sharp stock move reflects investor optimism around the ca…
(RTTNews) - Ernexa Therapeutics (ERNA) unveiled breakthrough preclinical results showing that its lead cell therapy candidate, ERNA-101 achieved complete tumor elimination and 100% long-term survival when combined with PD-1 blockade in syn…
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data…
Ernexa Therapeutics Inc. CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today anno…
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq:…
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV [https://seekingalpha.com/symbol/KALV]) and Intellia (NTLA [https://see…
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, tod…
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dis…
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected…
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of…
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of D…
The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1…
Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dis…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Cambium Networks Corp. 245,205,302 2.45 1.68 1.715 +1.097 Founder Group Lt…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at…
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev…
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented a…
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured…
CAMBRIDGE, Mass. - Ernexa Therapeutics (NASDAQ:ERNA) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing, the company announced Wednesday. The biotech firm, currently valued at $14.1 million, has seen…
Ernexa Therapeutics Inc. (NASDAQ:ERNA), a small-cap biotech company currently valued at $13.54 million and showing signs of financial strain according to InvestingPro data, announced a change in its independent registered public accounting…
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advis…
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) is registering 57.05M shares of common stock for resale by selling stockholders. * Includes 47.7M outstanding shares and 9.3M shares issuable upon exercise of pre-f…
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common St…
(RTTNews) - Ernexa Therapeutics (ERNA), a biotech firm focused on cell therapies for cancer and autoimmune diseases, will implement a 1-for-15 reverse stock split of its common shares, effective June 12, 2025. Trading on a split-adjusted b…
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) trades -19% as the Co. announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-15 [htt…
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued a…
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the…
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly o…
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at t…
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securitie…
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting…